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The main cause of prostate cancer related mortality is the development of hormone 
refractory disease. Circulating serum levels of IL-6 are raised in hormone refractory 
prostate cancer patients and evidence from cell line studies suggests that the IL-
6R/JAK/STAT3 pathway may be involved in development of this disease.  In the 
current study we investigate if expression levels of these family members are 
implicated in the development of hormone refractory prostate cancer. 
Immunohistochemistry using IL-6R, JAK1, STAT3, pSTAT3Tyr705 and pSTAT3Ser 727 
antibodies was performed on 50-matched hormone sensitive and hormone refractory 
tumours pairs.   
An increase in expression of cytoplasmic IL-6 receptor, with the development of 
hormone refractory prostate cancer was associated with reduced time to relapse 
(p=0.0074) whilst an increase in expression of cytoplasmic pSTAT3Tyr 705 was 
associated with reduced patient survival (p=0.0003).  In addition, those patients with 
high expression of cytoplasmic pSTAT3Tyr 705 in their hormone refractory tumours 
had significantly shorter time to death from biochemical relapse and overall survival 
in comparison to those patients with low expression of cytoplasmic pSTAT3Tyr 705 
(p=0.002 and p=0.0027, respectively).   
Activation of STAT3, via phosphorylation is associated with reduced patient survival, 
suggesting that activation of the IL-6R/JAK/STAT3 pathway is involved with 
development of hormone refractory prostate cancer. 
Keywords: prostate, cancer, IL-6, IL-6R, JAK, STAT, hormone refractory 
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Carcinoma of the prostate (CaP) is an increasing healthcare problem.  In the UK 
prostate cancer is the most common male malignancy and is the second main cause of 
cancer-related deaths among men. The majority of prostate cancer patients present 
with locally advanced or metastatic disease, which may be treated using androgen 
ablation therapy.  Response rates to androgen ablation therapy are initially high (70-
80%), however most patients relapse with resistance to androgen ablation within 18-
24 months, termed as developing hormone refractory prostate cancer (Beemsterboer 
et al., 1999). The lack of effective therapies directed against hormone refractory 
prostate cancer is related to the poor understanding of the molecular mechanisms that 
drive progression to this refractory state (McEwan, 2004).  .   
One possible mechanism underlying the development of hormone refractory 
prostate cancer is up-regulation of the IL-6 receptor/JAK/STAT3 cascade. As prostate 
cancer progresses from hormone sensitive to hormone refractory, the circulating 
concentrations of IL-6 in the serum of patients increases (Drachenberg et al., 1999; 
Fearon et al., 1991; Heinrich et al., 2003).  It is postulated that this results in 
activation of the IL-6 receptor/JAK/STAT3 cascade (Hobisch et al., 1998), which has 
previously been reported to increase androgen receptor activity  (Culig, 2003).  
Indeed, the increase in proliferation rate observed in prostate cancer cell line models 
in response IL-6 has been demonstrate to be via activation of STAT3 (Dhir et al., 
2002; Godoy-Tundidor et al., 2005;Sanford and Dewille, 2005).  In addition, in vitro 
studies have demonstrated that IL-6 dependent activation of the JAK/STAT3 pathway 
is accompanied by transition from hormone sensitive to hormone insensitive prostate 
cancer cell growth (Lee et al., 2003).  LNCaP cells, normally undergo apoptosis when 
androgens are withdrawn, however treatment with IL-6 or transfection with 
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constitutively active STAT3 results in protection of the cells from apoptosis and 
therefore resistance to androgen deprivation ((Lee et al., 2004).  Inhibition of STAT3 
activation results in the induction of apoptosis in cells even in the presence of IL-6 
(Barton et al., 2001; Barton et al., 2004).  The hypothesis that STAT3 is involved in 
the deveopment of hormone refractory prostate cancer is further supported by the 
observation that levels of activated STAT3 are significantly higher in androgen 
receptor negative cells (DU145 and PC3) than in androgen receptor positive (LNCaP 
cells) (Mora et al., 2002). STAT3 activation may therefore act to promote cell growth 
and survival in hormone refractory prostate cancer independent of the androgen 
receptor. 
Conversely, STAT3 has been implicated in the development of hormone 
refractory disease via interaction with the androgen receptor (Culig, 2003; Culig, 
2004).  In LNCaP cells the activated dimer of STAT3 binds ligand free androgen 
receptor in the cytoplasm before entering the nucleus, facilitating the translocation of 
the androgen receptor in to the nucleus in the absence of androgens (Chen et al., 2002; 
Matsuda et al., 2001).  Functional cell line studies demonstrate that the androgen 
receptor/STAT-3 complex can promote androgen regulated gene transcription even in 
the absence of androgens (Chen et al., 2002; Trachtenberg and Blackledge, 2002; 
Yamamoto et al., 2003).  This mechanism is supported by data that demonstrates IL-6 
can activate the androgen receptor in a ligand independent manner (Corcoran and 
Costello, 2003; Ueda et al., 2002).  Evidence in clinical tissue to support these in vitro 
observations are sparse, although it is reported that IL-6 receptor expression is 8 fold 
higher in prostate cancer tissue compared to normal tissue (Giri et al., 2001) and that 
phosphorylated STAT3 is observed in 82% of human prostate tumours and expression 
levels correlate with Gleason score (Barton et al., 2004).   
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In summary despite the large number of in vitro functional reports implying a role of 
IL-6R/JAK/STAT3 pathway in prostate cancer progression there appears to be little 
data confirming the role of this pathway in the development of clinical hormone 
refractory prostate cancer.  This study investigates both the expression levels and 
activation of the IL-6R/JAK/STAT3 pathway in matched hormone sensitive and 
hormone refractory tumours from the same patient.  This will enable us to assess if 
changes in expression and activation of pathway members are associated with 
development of hormone refractory prostate cancer.  Therefore, we aim to identify 
whether inhibition of this pathway would lead to improved patient outcome after 
progression to hormone refractory prostate cancer. 
 
MATERIALS AND METHODS 
 Patients 
Fifty patients were retrospectively selected for this study.  Ethical approval was 
obtained from the Multi-centre Research Ethics Committee (MREC Scotland) and 
Local Research Ethics Committees.  Inclusion criteria for this study were that each 
patient was required to have both hormone sensitive and hormone refractory tumour 
available for analysis. Tumours were defined as hormone sensitive if PSA fell by at 
least 50% during hormone treatment and subsequently hormone refractory if 2 
consecutive rises in serum PSA of >10% was observed during hormone therapy.   
 
 Immunohistochemistry 
All antibodies used in this study had specificity confirmed by western blotting and on 
paraffin embedded cell pellets know to express the proteins of interest (LNCaP and 
MCF-7 cells).  IHC was performed on 5 µm, archival formalin fixed paraffin 
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embedded prostate tumour sections.  Two methods of antigen retrieval were used, 
sections were microwaved under pressure (15 psi) in TE solution (5mM Tris base pH 
8.0 and 1mM Sodium EDTA (JAK1, 3332, Cell Signaling Technology, pSTAT3Tyr705, 
9131, Cell Signaling Technology and pSTAT3Ser727 9134, Cell Signaling Technology) 
or incubated in 10mM citrate buffer (Epitope retrieval solution x 10, 
DakoCytomation) in a calibrated water bath at 96oC for 20 minutes. (IL-6R, C20, SC-
661, Santa Cruz and STAT3, 9132, Cell Signaling Technology). Non specific 
background staining was blocked using 1.5% v/v normal horse serum in tri-phosphate 
buffered saline (TBS) and incubated for 20 minutes at room temperature.  All 
antibodies were incubated overnight at 4oC. The concentrations used for each 
antibody were as follows: IL-6R 1:500, JAK1 1:100, STAT3 1:100, pSTAT3Tyr705 
1:50 and pSTAT3Ser727 1:50.  Staining was developed using the LSAB plus kit 
(DakoCytomation, Glostrup, Denmark) and chromagen was detected using 
3,3’diaminobenzidine  (DAB) (Vector Labs, UK).  A positive and negative control 
slide was included in each IHC run, negative controls were incubated in an isotype 
matched control antibody at a concentration of 1mg/ml. 
 
Scoring Criteria 
Tissue staining was scored blind by 2 independent observers using a weighted 
histoscore method (Kirkegaard et al., 2006), also known as the H score system 
(McCarty, Jr. et al., 1986).  The full tissue section was examined and expression score 
calculated as follows (1 x % cells staining weakly positive) + (2 x % cells staining 
moderately positive) + (3 x % cells staining strongly positive).  Maximum score is 
300.  An interclass correlation coefficient (ICCC) for each protein was calculated by 
SPSS for Windows to confirm consistency between observers and the mean of the 
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two observers’ scores were used for analysis.  ICCC of greater than 0.7 is considered 
as excellent. (Kirkegaard et al., 2006) 
 
Statistical analysis 
Statistical analysis was performed using SPSS for Windows.  Descriptive analysis 
was used on variables such as age at diagnosis, serum PSA (pre- and post-relapse), 
Gleason sum, time to biochemical relapse, time to death from biochemical relapse and 
overall survival.  Median and inter-quartile ranges were calculated from these 
analyses.  In order to determine if there was a change in expression in progression 
from hormone sensitive to hormone refractory disease a Wilcoxon Signed Ranks test 
was used to compare the hormone sensitive expression score to the hormone 
refractory expression score for each protein and each location.  Survival analysis was 
performed using Kaplan Meier curves and the log rank test, low expression was 
defined as an expression score less than or equal to the median and high expression as 
expression score greater than the median.  A change in expression level in hormone 
sensitive and hormone refractory matched tumours were defined as the mean 
difference between the expression scores that each observer assigns for protein 
expression plus 2 standard deviations. The number of histoscore units defined as a 
change in expression for each individual protein are shown in table 1. 
 
RESULTS 
Patient Characteristics 
Fifty pairs of hormone sensitive and hormone refractory prostate cancer tumours were 
analysed.  The median age at diagnosis was 70 (inter quartile range (IQR) 64-73) 
years and the median PSA at diagnosis was 24.6 (IQR 6.4-79.8) ng/ml.  The median 
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time to biochemical relapse was 2.55 (IQR 1.55-5.24) years, the median time to death 
from hormone relapse was 1.49 (IQR 0.98-2.14) years and the median overall survival 
was 5.82 (IQR 3.03-6.78) years.  The median Gleason sum for hormone sensitive 
tumours was 8 (IQR 6-9) and for hormone refractory tumours was 9 (IQR 8-9).  The 
range of Gleason sum for both tumour types was 2-10.  All patients received chemical 
or surgical castration and 39 also received anti-androgens. 
 
Protein expression 
The variation in observer scoring was calculated by interclass correlation coefficient 
(ICCC). An ICCC of 0.7 is classed as excellent and an ICCC of 1 indicates identical 
scores.   All scorer variations assessed in this study by ICCC consistently achieved an 
ICCC of 0.7 or above, ICCC values for each protein at each cellular location is given 
in table 1.  
Membrane and cytoplasmic expression was observed for IL-6 receptor, while 
only cytoplasmic expression was observed for JAK1, and STAT3.  Cytoplasmic and 
nuclear expression was seen for both phosphorylated STAT3 proteins.  An example of 
a increase in expression for IL-6 receptor and pSTAT3Tyr705 in the transition from 
hormone sensitive to hormone refractory disease is shown in figure 1.  
 
Protein expression levels in hormone sensitive and hormone refractory tumours. 
In order to assess if protein expression levels were associated with clinical end points 
(relapse and survival), Kaplan-Meier graphs were plotted for tumours expressing low 
levels of specific proteins compared to high levels.  Those patients that expressed high 
levels of cytoplasmic pSTAT3Tyr705 in their hormone refractory tumour had 
significantly shorter time to death from biochemical relapse and than those patients 
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with low cytoplasmic pSTAT3Tyr705 expression (p=0.002, hazard ratio 4.25 (95% CI. 
1.59-11.34)(figure 2a). This also translated into significantly shorter overall survival 
(p=0.0027, hazard ratio 2.87(95% CI 1.39-5.92) (figure 2b).  The median overall 
survival in those patients whose tumours expressed high levels was 3.77 (IQR 1.11-
6.43) years compared with 7.55 (IQR 6.69-8.41) years for those whose tumours 
expressed low levels.  A trend with overall survival was also noted for nuclear 
pSTAT3Tyr705 in hormone refractory prostate cancer, however due the lines crossing 
after 8 years this was not significant (p=0.250) (figure 2c).  The median overall 
survival for those patients whose tumours had low expression was 7.49 (IQR 6.52-
8.57) years compared to 5.82 (IQR 3.49-8.15) years for those patients whose tumours 
expressed high levels of nuclear pSTAT3Tyr705.  Expression levels of all other proteins 
in hormone sensitive or hormone refractory tumours were not associated with time to 
relapse, time to death from relapse or overall survival.  When pSTAT3Tyr705 and 
pSTAT3Ser727 expression levels were divided by Gleason (<7, 7 or >7) no change in 
expression was observed in the cytoplasm or the nucleus.  In addition the ratio of 
pSTAT3Tyr705 and pSTAT3Ser727 does not correlate with Gleason.  
 
Changes in Protein Expression with the Development of hormone refractory prostate 
cancer 
An increase in cytoplasmic IL-6 receptor expression from hormone sensitive to 
hormone refractory was associated with reduced time to biochemical relapse 
(p=0.0074)(figure 3).  The median time to relapse for patients whose tumours had a 
decrease or no change in expression with the development of hormone refractory 
prostate cancer was 2.97 (IQR 1.89-4.07) year compared to 1.18 (IQR 0.45-1.92) 
years for those patients whose tumours exhibited a rise in expression.  
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An increase in expression of cytoplasmic pSTAT3Tyr 705 with progression to 
hormone refractory prostate cancer was also associated with a reduction in overall 
survival (p=0.0003, hazard ratio 4.52(95% CI 1.85-11.52)) (figure 4a).  The median 
overall survival for those patients whose tumours exhibited a decrease or no change in 
expression was 7.54 (IQR 6.52-8.57) years compared to 5.51 (IQR 2.77-8.26) years 
for those patients whose tumours exhibited a rise in expression.  Changes in the 
expression levels of all the other proteins investigated in the transition from hormone 
sensitive to hormone refractory tumours were not significantly associated with time to 
relapse, time to death from relapse or overall survival. 
DISCUSSION 
Approximately 50% of patients with advanced prostate cancer have elevated levels of 
serum IL-6 in comparison with men with normal prostates, benign prostatic 
hyperplasia, prostatitis and localized disease (Drachenberg et al., 1999; Twillie et al., 
1995).   In addition IL-6 has been associated with progression from hormone sensitive 
to hormone insensitive disease in animal models via interaction with AR cofactors 
(Wallner et al., 2006).  One possible mode by which IL-6 may influence progression 
of prostate cancer to the hormone refractory state is by activating the IL-6 
receptor/JAK1/STAT3 pathway, resulting in differentiation and inhibition of 
apoptosis (Smith et al., 2001; Spiotto and Chung, 2000a).  Over-expression of IL-6 
receptor in androgen sensitive human LNCaP cells results in the conversion to 
androgen independent growth both in vitro and in vivo (Lee et al., 2003) and depletion 
of IL-6 results in decreased proliferation of hormone insensitive cells but not hormone 
sensitive cells (Lou et al., 2000). 
The IL-6 receptor is predominantly located in the cell membrane (Lou et al., 2000), 
however the IL-6/IL-6 receptor complex may be taken into the cell by endocytosis as 
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part of the protein recycling process (Nesbitt and Fuller, 1992).  This is the cell’s 
method of down-regulating receptors once the ligand has produced the appropriate 
signal (Nesbitt and Fuller, 1992).  Therefore as the IL-6 receptor, unlike the other 
signaling proteins in the pathway does not have a phosphorylated form, the 
localization of the IL-6 receptor to the cytoplasm may be used as a surrogate marker 
for activation.  This study demonstrates that there is an association with an increase in 
cytoplasmic IL-6 receptor expression with development of hormone refractory 
prostate cancer and time to biochemical relapse. However these results should be 
treated with caution as only 12% (6 patients) of the patients in our cohort exhibited 
this increase.  We would therefore aim to increase our cohort size to confirm these 
results. 
JAK1 and STAT3 are proteins which become activated in sequence, upon the binding 
of IL-6 to the IL-6 receptor(Schindler and Darnell, Jr., 1995).  STAT3 is 
phosphorylated at two different sites, tyrosine 705 position and serine 727.  The 
tyrosine kinase, JAK1 phosphorylates STAT3 at tyrosine 705, while the kinase/s that 
mediate serine phosphorylation remain to be determined, evidence suggests that MAP 
kinase may be responsible (Briscoe et al., 1996b; Briscoe et al., 1996a).  
Immunohistochemical staining in our cohort of patients has demonstrated that both 
phosphorylated forms of STAT3, pSTAT3Tyr 705 and pSTAT3Ser727 are found in the 
cytoplasmic and nuclear compartments of the cell.  STAT3 dimerisation occurs in the 
cytoplasm before it enters the nucleus (Corcoran and Costello, 2003), the presence of 
activated STAT3 in the cytoplasm, therefore, provides a ‘snapshot’ of activated 
STAT3 before it enters the nucleus.  Although it has previously been reported that it is 
serine phosphorylation at 727 that modulates the DNA binding and/or transcriptional 
activity of STAT3 dimers (Dhir et al., 2002) our data shows no evidence of 
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pSTAT3Ser 727 being associated with development of hormone refractory prostate 
cancer.  However, it has been reported that phosphorylation of STAT3 at serine 727 
via ERK 1 or 2 ERK1 and 2 negatively regulates STAT3 activity ((Kim et al., 2002; 
Tian et al., 2004), this supports our data that pSTAT3Ser727 is not associated with 
development of hormone refractory prostate cancer or prostate cancer patient survival.    
There does however appear to be a significant role for pSTAT3Tyr 705 in the 
progression to hormone refractory prostate cancer.  High expression of cytoplasmic 
pSTAT3Tyr705 in hormone refractory prostate cancer tissue is associated with quicker 
time to death from hormone relapse and shorter overall survival.  In addition, an 
increase in pSTAT3Tyr 705 with the development of hormone refractory prostate cancer 
is associated with shorter overall survival.  These results fit with the hypothesis that 
activation of the IL-6 receptor/JAK1/STAT3 pathway is involved in the development 
of hormone refractory prostate cancer.  However, nuclear expression of pSTAT3Tyr705 
expression was not associated with clinical parameters in this study.  This may be due 
to the fact that although phosphorylation of tyrosine 705 increases STAT3 activity it 
is not sufficient to induce its relocation from the cytoplasm to the nucleus.  
Dimerisation of STAT3 is required for its translocation to the nucleus and this is 
regulated by reversible acetylation of a single lysine (Lys) residue (position 685) 
(Yuan et al., 2005).  More research is therefore required to understand the exact 
mechanisms for activation and translocation of STAT3 to the nucleus and also the 
consequence of STAT3 phosphorylation in clinical prostate cancer tissue.  Cell line 
studies demonstrate that STAT3 activation results in an increase in proliferation and 
induces neuroendocrine differentiation, although out with the scope of the current 
study these parameters warrant further investigation in clinical tissue in order to 
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establish the route by which STAT3 influences prostate cancer patient survival 
(Spiotto and Chung, 2000b). 
In summary, this data supports the hypothesis that the IL-6 
receptor/JAK1/STAT3 pathway is activated in the progression of hormone refractory 
prostate cancer.  Cytoplasmic expression of IL-6 receptor and pSTAT3Tyr 705 are 
associated with reduced time to biochemical relapse and reduced time to death from 
hormone relapse respectively, therefore, supporting the strategy for targeting this 
pathway in hormone refractory prostate cancer treatments. A recent report 
demonstrates that this pathway can be targeted and successfully inhibited in other 
disease using a humanized monoclonal antibody that targets the IL-6 receptor (in a 
similar to which herceptin targets HER2 (Jia et al., 2004; Nakahara and Nishimoto, 
2006; Nishimoto and Kishimoto, 2006a) and this approach has proved successful in 
prostate cancer animal models (Wallner et al., 2006).  Use of this drug  (tocilixumab) 
in phase II clinical trials for rheumatoid arthritis has proven the clinical benefit of IL-
6 blockade and we suggest that such a strategy should be applied to hormone 
refractory (Nishimoto and Kishimoto, 2006b). 
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Table  1 
 Mean Difference + 2 SD ICCC 
IL-6R (membrane) 
 
67.4 
 
0.85 
 
IL-6R (cytoplasmic) 
 
33.7 0.83 
JAK1 25.3 0.81 
STAT3 
 
32.5 0.86 
pSTAT3Tyr 705 
(cytoplasmic) 31.5 0.70 
pSTAT3Tyr 705 
(nuclear) 64.4 0.87 
pSTAT3Ser727 
(cytoplasmic) 18.7 0.93 
pSTAT3Ser727 
(nuclear) 54.9 0.87 
 
Table 1  shows the expression scores that represent a change in expression levels in 
the transition from hormone sensitive to hormone refractory disease.  These were 
calculated from the mean observer difference plus 2 standard deviations.  The inter 
class correlation coefficients are also shown demonstrating consistent scoring. P= 
phosphorylated. 
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Figure Legends 
 
Figure 1.  Images of matched hormone sensitive and hormone refractory prostate 
tumours whose expression increased in the transition from hormone sensitive to 
hormone refractory disease, (figure 1a IL-6 receptor and figure 1b pSTAT3Tyr705).  
Positive staining is brown in colour and is indicated by arrows according to their 
location, membrane (M), cytoplasm (C) and nucleus (N).  Counterstaining is blue and 
is represented in the stroma (S). 
Figure 2a shows Kaplan-Meier plot comparing time to death from biochemical 
relapse for those patients with hormone refractory tumours with high cytoplasmic 
pSTAT3Tyr705 expression (solid line)(27 patients) compared to those patients with 
hormone refractory tumours with low cytoplasmic pSTAT3Tyr705 expression (broken 
line)(23 patients) (p=0.002, hazard ratio 4.2(95% CI 1.59-11.34)). 
Figure 2b shows Kaplan-Meier plot comparing overall survival for those patients 
with hormone refractory tumours with high cytoplasmic pSTAT3Tyr705 expression 
(solid line)(19 patients) compared to those patients with hormone refractory tumours 
with low cytoplasmic pSTAT3Tyr705 expression (broken line)(31 patients) (p=0.0027, 
hazard ratio 2.87(95% CI  1.39-5.92)). 
Figure 2c shows a Kaplan Meier plot for high pSTAT3Tyr705 protein expression in the 
nucleus versus low nuclear pSTAT3Tyr705 protein expression in hormone refractory 
prostate tumours. Those patients with high pSTAT3Tyr705 (solid line)(22 patients) 
expression had shorter overall survival compared to those with low pSTAT3Tyr705 
(broken line)(28 patients), however this was not a significant change (p=0.25) 
Figure 3 shows a Kaplan Meier plot for an increase in IL-6R protein expression 
versus no change or a decrease in IL-6R protein expression in the transition from 
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hormone sensitive to hormone refractory disease. Those patients with an increase in 
IL-6R expression (solid line)(6 patients) had significantly shorter time to biochemical 
relapse compared to those with no change or a decrease in IL-6R expression (broken 
line) (45 patients) (p=0.0076, hazard ratio 3.45(95% CI  1.31-9.07)).   
Figure 4 shows a Kaplan Meier plot for an increase in pSTAT3Tyr705 protein 
expression in the cytoplasm versus no change or a decrease in pSTAT3Tyr705 protein 
expression in the transition from hormone sensitive to hormone refractory disease. 
Those patients with an increase in pSTAT3Tyr705 (solid line)(9 patients) expression 
had significantly shorter overall survival compared to those with no change or a 
decrease in pSTAT3Tyr705 expression (broken line) (50 patients) (p=0.0003, hazard 
ratio 4.52(95% CI  1.85-11.52)).   
 
